Nutlin-3

Catalog No.S1061

Nutlin-3 Chemical Structure

Molecular Weight(MW): 581.5

Nutlin-3 is a potent and selective Mdm2 (RING finger-dependent ubiquitin protein ligase for itself and p53) antagonist with IC50 of 90 nM in a cell-free assay; stabilizes p73 in p53-deficient cells.

Size Price Stock Quantity  
In DMSO USD 185 In stock
USD 110 In stock
USD 170 In stock
USD 370 In stock
USD 970 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

4 Customer Reviews

  •  

    p53 activation in A76T p53-mutated UKF-NB-3’RITA(10 uM) IV cells. Cells were treated with RITA (10 uM) or nutlin-3 (10 uM) for 24 h and investigated by western blot for the expression of p53 target genes

    Cell death dis 2012 3, e294. Nutlin-3 purchased from Selleck.

    Caspase 3/7 activation in UKF-NB-3 or UKF-NB-3rNutlin10 μM cells treated nutlin-3 (10 μM), VCR (10 ng/ml), DOX (20 ng/ml), or CDDP (1000 ng/ml).

    Cell Death Dis 2011 2, e243. Nutlin-3 purchased from Selleck.

  • Ubiquitination of p53 in vivo by BIRC6 in the presence of Nutlin-3. Cells were treated with Nutlin-3 (20 uM, 24 h) before harvest. Cell lysates were immunoprecipitated with anti-p53 antibody and immunoblotted by anti-ubiquitin antibody.

    Int J Oncol 2014 44, 761-8. Nutlin-3 purchased from Selleck.

    d qPCR evaluation of DKK1 in MSCs exposed to melphalan in combination with increasing concentrations of nutlin-3 for 24 h. Cells were pre-treated with nutlin-3 for 20 min prior to chemotherapy. *Indicates p value<0.05, One-way ANOVA with Holm-Sidak post hoc

    Med Oncol, 2016, 33(10):113. Nutlin-3 purchased from Selleck.

Purity & Quality Control

Choose Selective Mdm2 Inhibitors

Biological Activity

Description Nutlin-3 is a potent and selective Mdm2 (RING finger-dependent ubiquitin protein ligase for itself and p53) antagonist with IC50 of 90 nM in a cell-free assay; stabilizes p73 in p53-deficient cells.
Targets
Mdm2 [5]
(Cell-free assay)
180 nM
In vitro

Nutlin-3 potently inhibits the MDM2-p53 interaction, leading to the activation of the p53 pathway. Nutlin-3 treatment induces the expression of MDM2 and p21, and displays potent antiproliferative activity with IC50 of ~1.5 μM, only in cells with wild-type p53 such as HCT116, RKO and SJSA-1, but not in the mutant p53 cell lines SW480 and MDA-MB-435. In SJSA-1 cells, Nutlin-3 treatment at 10 μM for 48 hours significantly induces caspase-dependent cell apoptosis by ~45%. Although Nutlin-3 also inhibits the growth and viability of human skin (1043SK) and mouse embryo (NIH/3T3) with IC50 of 2.2 μM and 1.3 μM, respectively, cells remain viable 1 week post-treatment even at 10 μM of Nutlin-3, in contrast with the SJSA-1 cells with viability lost at 3 μM of Nutlin-3 treatment. [1] Nutlin-3 does not induce the phosphorylation of p53 on key serine residues and reveals no difference in their sequence-specific DNA binding and ability to transactivate p53 target genes compared with phosphorylated p53 induced by the genotoxic drugs doxorubicin and etoposide, demonstrating that phosphorylation of p53 on key serines is dispensable for transcriptional activation and apoptosis. [2] Although binding less efficiently to MDMX than to MDM2, Nutlin-3 can block the MDMX–p53 interaction and induce the p53 pathway in retinoblastoma cells (Weri1) with IC50 of 0.7 μM. [3] Nutlin-3 at 30 μM also disrupts endogenous p73-HDM2 interaction and enhances the stability and proapoptotic activities of p73, leading to the dose-dependent cell growth inhibition and apoptosis induction in cells without wild-type p53. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MCF7 Mn3HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1rpRVXDqM7:TR?= MX60POKhcA>? MXvicI9kc3NiMketU2hENWmwZIXj[YQh[2WubDDwdo9tcW[ncnH0bY9vKGOxbYDhdoFjdGVidH:geIhifCCxZjDiZZNidCCuZY\lcJM> NUHxN5dxOjZ|NUC1OlU>
NP69 M4DtdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTNzLk[5xtEzNjV2IN88US=> MoDMNlYzPTJ3N{W=
NP460 NID3SY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTJ{Lki1xtEyNjF6IN88US=> MVSyOlI2OjV5NR?=
C666-1 NFfrc3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2DwTGlEPTB;MUmuPVXDuThwOUOg{txO NULPSoZ4OjZ{NUK1O|U>
C666-1 M1PIcmNmdGxiVnnhZoltcXS7IFHzd4F6 NEDRe5IyOCEEtV2= MYC0PEBp NUH0PHhVTE2VTx?= MljJd4Vve2m2aYrld{BEPjZ4LUGgZ4VtdHNidH:geIhmKGO7dH;0c5hq[yCnZn\lZ5Qhd2ZiY3nzdIxifGmw MknvNlYzPTJ3N{W=
C666-1  MXTGeY5kfGmxbjDBd5NigQ>? NV;y[ol1OTBiwsXN NFf5SHMzPCCq M13TfGROW09? M4nte4FkfGm4YYTld{B1cGVicEWzJJBifGi5YYmsJJVxemWpdXzheIlv\yCyNUOsJJAzOSCjbnSgUYRuOg>? NG\MS4szPjJ3MkW3OS=>
C666-1 MV;BdI9xfG:|aYOgRZN{[Xl? M{XiTVExKML3TR?= MXe0PE84OiCq MYjEUXNQ M33tb5NmdnOrdHn6[ZMhSzZ4Nj2xJINmdGy|IITvJINqe3CuYYTpck1qdmS3Y3XkJIFxd3C2b4Ppdy=> NEfMeWMzPjJ3MkW3OS=>
A549 M2DuUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDONY8zPCCq NFPCRYRKSzVyPUG3MlY5KMLzIESuOVIh|ryP NWe2PJRzOjZzMkWyN|A>
A549-NTC MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1jRZlI1KGh? M4X5PGlEPTB;MUmuOFIhyrFiMT65OkDPxE1? MYSyOlEzPTJ|MB?=
A549-920 MojpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX6yOEBp NVXKU|Z6UUN3ME2zN{45PSEEsTC0Mlg1KM7:TR?= NXj0cFJkOjZzMkWyN|A>
CRL-5908 NVT3bm1RT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17FUFI1KGh? MUPJR|UxRTN6LkexJOKyKDJwNEOg{txO MWiyOlEzPTJ|MB?=
L6 MnXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEXTWnEyOMLizszNxsA> NFmz[IkzPC92OD:3NkBp MYDEUXNQ M{HGcolvcGmkaYTzJINmdGy|IIDyc4xq\mW{YYTpc44h[W6mIHTp[oZmemWwdHnheIlwdg>? MXWyOVg4OTd7NB?=
C2C12 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXvVWWM3OTEEoN88UeKh M1\mPVI1NzR6L{eyJIg> NU\ETIMyTE2VTx?= M{PHVolvcGmkaYTzJINmdGy|IIDyc4xq\mW{YYTpc44h[W6mIHTp[oZmemWwdHnheIlwdg>? Mk\jNlU5PzF5OUS=
MCF-7  MUfGeY5kfGmxbjDBd5NigQ>? MWixNOKh|ryP MUXEUXNQ MoXxbY5pcWKrdIOgZ5lkdGmwIFSxJIFv\CCGaXPlduKh NXLVUJkxOjV5MEK3NFM>
DU4475  MVnGeY5kfGmxbjDBd5NigQ>? M1PSU|UwOTBxMkCg{txO NGWzR3MzPMLiaB?= M{PwW4Rwf26{ZXf1cIF1\XNiVH;jZU0yKGSxc3Wg[IVx\W6mZX70cJk> M1\XOVI2PTR5MUe0
SMMC-7721 M2XBR2Z2dmO2aX;uJGF{e2G7 NIrqfncyOCEQvF2= NXLXTodpPDhiaB?= M13BeGROW09? M{PkdINifXOnczDEUmEhTFOEIHThcYFo\Q>? NHXnO|YzPTV2NEO2NS=>
SMMC-7721 NY[3TlVNTnWwY4Tpc44hSXO|YYm= M1;HdlExKM7:TR?= NVXQTGtIPDhiaB?= M1u5V2ROW09? MYPpcoR2[2W|IITo[UBkcHKxbXH0bY4u[m:3bnSgdJJwfGWrbjDJSmkyPiC2bzDwZZJ1cWGubImgcI9k[WyrenWgbY4hfGinIHP5eI9xdGG|bdMg M3nUNlI2PTR2M{[x
SMMC-7721 NIfpPZRHfW6ldHnvckBCe3OjeR?= MVSxNEDPxE1? NXvPe3dGPDhiaB?= MmfVSG1UVw>? NH\ZcVNqdmO{ZXHz[ZMhfGinIHX4dJJme3Orb36gcIV3\Wxib3dCpGlHVkJzwrDtVm5C MVWyOVU1PDN4MR?=
SMMC-7721 NHG2[mlHfW6ldHnvckBCe3OjeR?= NGHuVIIyOCEQvF2= MWezOkBp M2fBO2ROW09? NFvJcpFk[XW|ZYOgeIhmKGWldH;wbYMh\XiycnXzd4lwdiCxZjDJSmkyPg>? M4fNUlI2PTR2M{[x
MCF-7 M3Lzd2Z2dmO2aX;uJGF{e2G7 NVn6e|hQOTEEoN88US=> MVywMVI1KGh? MWjpcoR2[2W|IIC1N{BidmRicEKxM2NqeDF? NEfs[HczPTR6MkO3Ny=>
OVCAR10 Mmj5SpVv[3Srb36gRZN{[Xl? NHrOVIcyOMLizszN NX;1N|NTOjGqwrC= M2XIOWROW09? NYr4doJXcW6lcnXhd4V{KHB3MzDwdo91\WmwIHzleoVtew>? NVXHOIx5OjV2Mk[1OFg>
NCI-H23 MX;GeY5kfGmxbjDBd5NigQ>? NY\3OJNDOTEEoN88US=> MVyyNYjDqA>? MUHEUXNQ MlLWbY5kemWjc3XzJJA2OyCycn;0[YlvKGyndnXsdy=> MWOyOVQzPjV2OB?=
A2780 NIi1W2JHfW6ldHnvckBCe3OjeR?= MmjHNVDDqM7:TR?= MUGyNYjDqA>? NVTQOJhjTE2VTx?= NYD1d3hHcW6lcnXhd4V{KHB3MzDwdo91\WmwIHzleoVtew>? NWXk[oVWOjV2Mk[1OFg>
NCI-H23 MmC0SpVv[3Srb36gRZN{[Xl? NHHxVVYyOMLizszN NIHOc4kzOWkEoB?= MnvPSG1UVw>? NVXoUGpp\GWlcnXhd4V{KHSqZTDGc5hOOSCuZY\lcJM> MXKyOVQzPjV2OB?=
A2780 M2TUcGZ2dmO2aX;uJGF{e2G7 M1fWcFExyqEQvF2= MoezNlFpyqB? NIDJPJVFVVOR NXrhVI86\GWlcnXhd4V{KHSqZTDGc5hOOSCuZY\lcJM> M1exO|I2PDJ4NUS4
HCT116  Mn3YSpVv[3Srb36gRZN{[Xl? Mlq0NVAhyrWP NIXa[2IzPCCq M1n4[INifXOnczDhJJA2Oy2mZYDlcoRmdnRidHX0doFxdG:rZDDHNU1ienKnc4SgbY4h\GmybH;p[EBJS1RzMU[gZ4xwdmW|IFSzJIFv\CCGOB?= MnS4NlU{QDByNUW=
MCF-10CA1a NE\Je|lHfW6ldHnvckBCe3OjeR?= NWfRXlltOTEEoN88US=> NGnCZoE1QCCq Mo\tSG1UVw>? MX3pcohq[mm2czDiZZNidCCrbo\hd4lwdiCjbnSgdoVlfWOnZDDUS2Yu|rJ|LXnu[JVk\WRiaX72ZZNqd25idH:gZoF{[WxibHX2[Yx{ NIDsOVgzPTJ3N{eyPS=>
MCF-10A1  MW\GeY5kfGmxbjDBd5NigQ>? NEjNV3UyOMLizszN MYGyOE81QCCq MkjuSG1UVw>? NX\EeJJucW6qaXLpeJMhdWmpcnH0bY9vKG:oIH7vdo1idCCkcnXhd5Qh\XCrdHjlcIlidMLi Mk\iNlUzPTd5Mkm=
MCF-10CA1a NXHQepE6TnWwY4Tpc44hSXO|YYm= M3S1RVExyqEQvF2= MlrkNlQhcA>? M2focmROW09? NEnmUGFl\WO{ZXHz[ZMhfGinIGTHSk3PujNvaX7keYNm\CCvUl7BJIxmfmWuczDv[m1OWDJuwrDNUXA6NCCjbnVCpIlvfGWpcnnuxsDPusLiMx?= M36zUVI2OjV5N{K5
MCF-10CA1a NIrtPWdHfW6ldHnvckBCe3OjeR?= NWC3[ZpROTEEoN88US=> NXHLTFNXOjRiaB?= NXrofW15TE2VTx?= NVmyRYxJcW6qaXLpeJMhKFSJRj5OtlMucW6mdXPl[EBGWEiEMtMgcXJPSSCjbnSgdJJwfGWrbjDlfJBz\XO|aX;u M4K5VVI2OjV5N{K5
SK-BR-7 MUjGeY5kfGmxbjDBd5NigQ>? NIPuXmQyOMLizszN NUHaOIRXOjRiaB?= MXrEUXNQ MYnpcohq[mm2czCgWGdHNc7{Mz3pcoR2[2WmIFXQTGIzyqCvUl7BJIFv\CCycn;0[YlvKGW6cILld5Nqd25? NG\keYszPTJ3N{eyPS=>
SUM102PT NFTH[JVHfW6ldHnvckBCe3OjeR?= NVH4elYyOTEEoN88US=> NEO5U2ozPCCq MUPEUXNQ M1rDR4lvcGmkaYTzJEBVT0ZvzsKzMYlv\HWlZXSgSXBJSjMEoH3SUmEh[W6mIIDyc5RmcW5iZYjwdoV{e2mxbh?= NGHiR4MzPTJ3N{eyPS=>
RAW 264.7 MnfBSpVv[3Srb36gRZN{[Xl? MX6xNOKh|ryP MnjKN|AhdWmw M3TVOpBz\X[nboTzJJRp\SCyNUOgdoVlfWO2aX;uJIlvKHKnc4DvcpNmKHSxIFzQVy=> M4PUSFI2OTd{NUS3
RAW 264.7 M1rk[mZ2dmO2aX;uJGF{e2G7 M376e|ExyqEQvF2= M2O1elMxKG2rbh?= MmHGdoVlfWOnczD0bIUhVFCVLXH1[41mdnSnZDD0bIUhVkZvzsrCJIx2[2moZYLhd4UhemWyb4L0[ZIh\2WwZTDhZ5Rqfmm2eR?= NV3V[nJ[OjVzN{K1OFc>
RAW 264.7 NVLydFhLTnWwY4Tpc44hSXO|YYm= NHvpXFkyOMLizszN MkPUN|AhdWmw NEDOdnVqdmirYnn0d{BNWFNvaX7keYNm\CCQTzDwdo9lfWO2aX;uxsA> MYqyOVE4OjV2Nx?=
MCF7  MV\D[YxtKF[rYXLpcIl1gSCDc4PhfS=> MlP0Nk42KML3TR?= MYW1JIQ> M37CRmROW09? NELoS|h{\W6|aYTpfoV{KE2FRkegeI8hWEGUUDDpcohq[mm2aX;u MlrENlUxQDV7MEK=
MCF7  NYe5NHM6TnWwY4Tpc44hSXO|YYm= M3PsPFIvPSEEtV2= NWLaXpBsPDhiaB?= NYHoTG9{TE2VTx?= Mof3[IVkemWjc3XzJJRp\SCqb33vcI9od3W|IFTTRkBz\XCjaYKg[pJmeXWnbnPp[ZM> NH;FXogzPTB6NUmwNi=>
ACHN M4fGW2NmdGxiVnnhZoltcXS7IFHzd4F6 NUjNcIh{OC53LUGwJO69VQ>? M4jP[VAuPiCm NEfHT4NFVVOR MlThbY5pcWKrdIOgdJJwdGmoZYLheIlwdiCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NFjMVVAzPTB4N{e4Oy=>
Caki-2 MkjCR4VtdCCYaXHibYxqfHliQYPzZZk> MXGwMlUuOTBizszN M1jHNFAuPiCm MnXWSG1UVw>? NWPyZoFqcW6qaXLpeJMheHKxbHnm[ZJifGmxbjDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MmPvNlUxPjd5OEe=
A498 MkXoR4VtdCCYaXHibYxqfHliQYPzZZk> MkLhNE42NTFyIN88US=> NYfoPXgyOC14IHS= M3nTR2ROW09? MlvobY5pcWKrdIOgdJJwdGmoZYLheIlwdiCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NYHs[YhEOjVyNke3PFc>
115 MlvxR4VtdCCYaXHibYxqfHliQYPzZZk> NX[2UJR5OC53LUGwJO69VQ>? M4fsOlAuPiCm Mnf6SG1UVw>? NW\XdlhPcW6qaXLpeJMheHKxbHnm[ZJifGmxbjDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NFzRN|UzPTB4N{e4Oy=>
117 MoLIR4VtdCCYaXHibYxqfHliQYPzZZk> NHW0bHUxNjVvMUCg{txO NHnTRXAxNTZiZB?= MojBSG1UVw>? NGL4dpJqdmirYnn0d{Bxem:uaX\ldoF1cW:wIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MXeyOVA3Pzd6Nx?=
ACHN M1:yXWZ2dmO2aX;uJGF{e2G7 NFjsV5cxNjVxMT:1JO69VQ>? NY\hWI9FPDhiaB?= M1vhSWROW09? NFj4PIVt\WGmczD0c{BqdmO{ZXHz[YQh\XiycnXzd4lwdiCxZjDwOVMh[W6mIIPvcYUheDV|IIThdodmfCCpZX7ld|ohVUSPMjygZY5lKHB{MR?= MUSyOVA3Pzd6Nx?=
Caki-2 MYnGeY5kfGmxbjDBd5NigQ>? MknaNE42NzFxNTFOwG0> NGi2WoI1QCCq MkfnSG1UVw>? MlXCcIVi\HNidH:gbY5kemWjc3XkJIV5eHKnc4Ppc44hd2ZicEWzJIFv\CC|b33lJJA2OyC2YYLn[ZQh\2WwZYO6JG1FVTJuIHHu[EBxOjF? NHn2dWEzPTB4N{e4Oy=>
A498 MnrxSpVv[3Srb36gRZN{[Xl? M3v6[lAvPS9zL{Wg{txO NHvhXZk1QCCq Mo\CSG1UVw>? MVns[YFleyC2bzDpcoNz\WG|ZXSg[ZhxemW|c3nvckBw\iCyNUOgZY5lKHOxbXWgdFU{KHSjcnfleEBo\W6nc{qgUWROOixiYX7kJJAzOQ>? MYiyOVA3Pzd6Nx?=
115 NIn0T2dHfW6ldHnvckBCe3OjeR?= MmHuNE42NzFxNTFOwG0> MnvJOFghcA>? MoDXSG1UVw>? M4H2WIxm[WS|IITvJIlv[3KnYYPl[EBmgHC{ZYPzbY9vKG:oIIC1N{BidmRic3;t[UBxPTNidHHy[4V1KGenbnXzPkBOTE1{LDDhcoQheDJz NF7PRZkzPTB4N{e4Oy=>
ACHN M{Gxbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPHOUDPxE1? Ml7UOFghcA>? M2flSmROW09? MmqwbY5lfWOnczDj[YxtKGO7Y3zlJIFzemW|dNMg NGjrUZQzPTB4N{e4Oy=>
Caki-2 Mn:4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoH5OUDPxE1? NXjIZVZnPDhiaB?= MY\EUXNQ M3LuTIlv\HWlZYOgZ4VtdCCleXPs[UBienKnc4VCpC=> Ml2zNlUxPjd5OEe=
A498 M2fRZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;h[4ZGPSEQvF2= NITZOXU1QCCq NFzVb2FFVVOR Mo\JbY5lfWOnczDj[YxtKGO7Y3zlJIFzemW|dNMg MXKyOVA3Pzd6Nx?=
115 M2fSbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYS1JO69VQ>? MU[0PEBp NUn1OI1FTE2VTx?= MorjbY5lfWOnczDj[YxtKGO7Y3zlJIFzemW|dNMg Ml\2NlUxPjd5OEe=
ACHN MX;GeY5kfGmxbjDBd5NigQ>? M2rPRVUh|ryP M33yUVQ5KGh? NHPLOWpFVVOR M1XWTIlv\HWlZYOgdFU{NWSncHXu[IVvfCC|ZX7ld4NmdmOnwrC= NXzXTGx3OjVyNke3PFc>
Caki-2 MXHGeY5kfGmxbjDBd5NigQ>? Mm\sOUDPxE1? NWLWfnJ3PDhiaB?= M1jZOmROW09? M4TpUYlv\HWlZYOgdFU{NWSncHXu[IVvfCC|ZX7ld4NmdmOnwrC= NUewTYg6OjVyNke3PFc>
A498 MYfGeY5kfGmxbjDBd5NigQ>? NVX0dIo4PSEQvF2= NVrtb4VHPDhiaB?= NULRcHUxTE2VTx?= NIrNbnlqdmS3Y3XzJJA2Oy2mZYDlcoRmdnRic3Xu[ZNk\W6lZdMg NXXyR3YzOjVyNke3PFc>
115 NF\UVIZHfW6ldHnvckBCe3OjeR?= MkXXOUDPxE1? NWXPWFlsPDhiaB?= NX;yZVB4TE2VTx?= MV7pcoR2[2W|IIC1N{1l\XCnbnTlcpQhe2WwZYPj[Y5k\cLi NUDkWmRUOjVyNke3PFc>
MOLM-13 MXPGeY5kfGmxbjDBd5NigQ>? MXS2xsDPxE1? MXSwMVghcA>? MULEUXNQ M{T0PYlv[3KnYYPld{B1cGVibHX2[Yx{KG:oIIC1N{whVUSPMjygdFIyKGGwZDDhZ4V1gWyjdHXkJJA2Ow>? M4TJN|I1QDh3MEiy
MOLM-13 MUXGeY5kfGmxbjDBd5NigQ>? MYK2xsDPxE1? NFLzUXQ3KGh? NGPYRplFVVOR M3T2b4VvcGGwY3XzJJRp\SCjY3X0fYxifGmxbjDv[kBpcXO2b37lJGgzSiCjbnSgbIVifCC|aH;jb{Bxem:2ZXnud{BJe3B{NzDhcoQhUHOyOUC= MViyOFg5PTB6Mh?=
HepG2 Mn;CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDlO|IhcA>? MmXoSG1UVw>? NEnkU2tKSzVyPUO1Mlg3KMLzIEKuPUDPxE1? M1zLblI1QDh2OEC5
HepG2/As M1XJTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYP2OHR2PzJiaB?= Mm\GSG1UVw>? M4PNfGlEPTB;NkiuNVMhyrFiOT62JO69VQ>? NVXuOlBTOjR6OES4NFk>
SMMC7721 M4jlOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHyO|IhcA>? MkXQSG1UVw>? NV\INVJ6UUN3ME2zNU4zQCEEsTC0MlIh|ryP MWOyOFg5PDhyOR?=
SMMC7721/Ac MmXnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX3ZTFBuPzJiaB?= NWPkeWZWTE2VTx?= MorITWM2OD13NT6yNUDDuSB3LkCzJO69VQ>? MXqyOFg5PDhyOR?=
Huh-7 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIPocWk4OiCq M2D6S2ROW09? MXnJR|UxRTN|Lkm2JOKyKDNwOTFOwG0> NGPadJIzPDh6NEiwPS=>
Hep3B MlTDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHq4NIk4OiCq MmTmSG1UVw>? NHvSUoRKSzVyPUKwMlE5KMLzIEGuPFQh|ryP NUTJVIVLOjR6OES4NFk>
HepG2 NHrPN4VCeG:ydH;zbZMhSXO|YYm= Ml;tbY5lfWOnczDhdI9xfG:|aYO= MWmyOFg5PDhyOR?=
SMMC7721 NXjEcHZTSXCxcITvd4l{KEG|c3H5 M3HqN4lv\HWlZYOgZZBweHSxc3nz Mn3yNlQ5QDR6MEm=
Huh-7 MofGRZBweHSxc3nzJGF{e2G7 MWjpcoR2[2W|IHHwc5B1d3Orcx?= NX\DcVBWOjR6OES4NFk>
Hep3B MX;BdI9xfG:|aYOgRZN{[Xl? MYfpcoR2[2W|IHHwc5B1d3Orcx?= M1HyeFI1QDh2OEC5
U2OS  NIHRemVHfW6ldHnvckBCe3OjeR?= MYOyNEDPxE1? NWXZdHF1OjRiaB?= NVjMbJNscW6lcnXhd4V{KHSqZTDtVm5CKGyndnXsd{Bw\sLiQlPMNmEyNCCEQ1zYUOKh[W6mQlPMWy=> NVWxS2RsOjR6NkeyOVk>
AML2 NX;sbGs4SXCxcITvd4l{KEG|c3H5 NXfofFhbOi9zMDFOwG0> NXHZclE3OjRxNEigbC=> M{HZTYlv\HWlZYOgZZBweHSxc3nz MnnsNlQ3PTl5NEm=
MOML13 MXrBdI9xfG:|aYOgRZN{[Xl? NGizdWQzNzFyIN88US=> NUDJZYxROjRxNEigbC=> M1HsTIlv\HWlZYOgZZBweHSxc3nz M2TaWlI1PjV7N{S5
AML2 M{PNOmZ2dmO2aX;uJGF{e2G7 MmLpNVDPxE1? NVjmRYY1Oi92IHi= NWnTTZVjcW6lcnXhd4V{KHSqZTDs[ZZmdCCxZjDwOVM> NV:zbI4yOjR4NUm3OFk>
AML3 M4TMTGZ2dmO2aX;uJGF{e2G7 NVXjZYs{OTEQvF2= Mlq5Nk81KGh? M2DHR4lv[3KnYYPld{B1cGVibHX2[Ywhd2ZicEWz M2DRV|I1PjV7N{S5
MOML13 M4\NbWZ2dmO2aX;uJGF{e2G7 NY\yb3BQOTEQvF2= MYiyM|QhcA>? NG\BSplqdmO{ZXHz[ZMhfGinIHzleoVtKG:oIIC1Ny=> MVuyOFY2QTd2OR?=
BeWo NEnGZlJHfW6ldHnvckBCe3OjeR?= M2GyV|MxKML3TR?= NU\FU|V[OjRiaB?= MX7pcoNz\WG|ZYOgdFU{NCCPZH2yMEBxOjFiYX7kJHB2dWFiYYSgeIhmKHC{b4TlbY4hdGW4ZXy= NISzZXUzPDR7OEG1OC=>
BeWo M{H1V2Fxd3C2b4Ppd{BCe3OjeR?= NITJ[3Q{OCEEtV2= MoDpNlQhcA>? MVrpcoNz\WG|ZYOgZZBweHSxc3nz NF\nO24zPDR7OEG1OC=>
OCI NUPyc5J3TnWwY4Tpc44hSXO|YYm= MYKxNEDPxE1? NGS0b|QzPCCq M3m0d5VxemWpdXzheIV{KHSqZTDTU2NUNTFiZYjwdoV{e2mxbh?= MkXFNlQ1PzN3NkK=
MOLM NXvSelQ3TnWwY4Tpc44hSXO|YYm= MV2xNEDPxE1? MmD5NlQhcA>? M{PoPZVxemWpdXzheIV{KHSqZTDTU2NUNTFiZYjwdoV{e2mxbh?= MnS1NlQ1PzN3NkK=
U2OS  MXfGeY5kfGmxbjDBd5NigQ>? NW\oOppHOjBizszN MoXoNlQhcA>? NYW3e4hucW6lcnXhd4V{KHSqZTDs[ZZmdHNib3[geIhmKEiRLUGgdJJwfGWrbjDhd{B4\WyuIHHzJJRp\SCyNUOgdJJwfGWrbh?= NVvZfFN6OjR|Nk[wNFc>
RKO MmnuSpVv[3Srb36gRZN{[Xl? M4DBdVIxKM7:TR?= NVfGS4xrOjRiaB?= NVrwS3BZcW6lcnXhd4V{KHSqZTDs[ZZmdHNib3[geIhmKEiRLUGgdJJwfGWrbjDhd{B4\WyuIHHzJJRp\SCyNUOgdJJwfGWrbh?= MlS1NlQ{PjZyMEe=
U2OS  M3iwZmZ2dmO2aX;uJGF{e2G7 NHrSfZkzOCEQvF2= NXjTbVV[OjRiaB?= Ml34bY5lfWOnczDIU{0yKGW6cILld5Nqd25iYYSgeIhmKGyndnXsJI9nKHS{YX7zZ5JqeHSrb36= NEjmRmozPDN4NkCwOy=>
RKO MlX2SpVv[3Srb36gRZN{[Xl? NETn[pUzOCEQvF2= NUC5dZdSOjRiaB?= M1XjWolv\HWlZYOgTG8uOSCneIDy[ZN{cW:wIHH0JJRp\SCuZY\lcEBw\iC2cnHud4NzcXC2aX;u NEHyWWMzPDN4NkCwOy=>
SMMC-7721  M1e0WmNmdGxiVnnhZoltcXS7IFHzd4F6 M3KzdVEvOjVvMkCg{txO M{XRbVI1NzR6L{eyJIg> NVXXSFAxTE2VTx?= NH;tZWNqdmirYnn0d{Bk\WyuIIDyc4xq\mW{YYTpc44h\G:|ZTDhcoQhfGmvZTDk[ZBmdmSnboTsfS=> M4HoRlI1Ojh4M{Gy
HuH-7 MXfD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MoTFNU4zPS1{MDFOwG0> NEXnc4MzPC92OD:3NkBp MkjsSG1UVw>? M1rySolvcGmkaYTzJINmdGxicILvcIln\XKjdHnvckBld3OnIHHu[EB1cW2nIHTldIVv\GWwdHz5 M4\TcFI1Ojh4M{Gy
SMMC-7721  MmDQRZBweHSxc3nzJGF{e2G7 MWeyNEDPxE1? MmiyOFghcA>? NYPNfYZZTE2VTx?= MnTPbY5lfWOnczDhdI9xfG:|aYO= M4TSSlI1Ojh4M{Gy
HuH-7 NGrGbGtCeG:ydH;zbZMhSXO|YYm= MUGyNEDPxE1? M3LUc|Q5KGh? NGT4SYxFVVOR MWPpcoR2[2W|IHHwc5B1d3Orcx?= NULh[nhyOjR{OE[zNVI>
SMMC-7721  NVLudnlvTnWwY4Tpc44hSXO|YYm= M3vxd|ExKM7:TR?= MVOzOkBp MYLEUXNQ NV3xTpJL\G:5bj3y[Yd2dGG2ZYOgeIhmKHC{b4TlbY4h\XiycnXzd4lwdiCuZY\lcEBw\iCyaH;zdIhwNVOnckO5Nk1xPTN? M2HHSFI1Ojh4M{Gy
HuH-7 NUTRNoZMTnWwY4Tpc44hSXO|YYm= MnrTNVAh|ryP NInmdHY{PiCq NVXMZXB1TE2VTx?= Mn7v[I94di2{ZXf1cIF1\XNidHjlJJBzd3SnaX6g[ZhxemW|c3nvckBt\X[nbDDv[kBxcG:|cHjvMXNmejN7Mj3wOVM> MXmyOFI5PjNzMh?=
AT2 MlfwSpVv[3Srb36gRZN{[Xl? NVzWTJJtPS9zMDFOwG0> M{DKO4xm[WS|IITvJIEhe3Wkc4ThcpRq[WxiYXPjeY12dGG2aX;uJI9nKHSqZTDwOVMheHKxdHXpckBieyC5ZXzsJIF{KHSqZTDlfJBz\XO|aX;uJI9nKGm2czDkbZJm[3RidHHy[4V1eyCyMkGsJG1FVTJiYX7kJJRp\SCycn:tZZBweHSxdHnjJGJCYCCjbnSgVHVOSSCycn;0[Ylve8Li MXOyOFI1ODJyMx?=
REH NWLLUmZuTnWwY4Tpc44hSXO|YYm= NG[4eW02NzFyIN88US=> NWfMV|F7dGWjZIOgeI8h[SC|dXLzeIFvfGmjbDDhZ4N2dXWuYYTpc44hd2ZidHjlJJA2OyCycn;0[YlvKGG|IIflcIwh[XNidHjlJIV5eHKnc4Ppc44hd2ZiaYTzJIRqemWldDD0ZZJo\XS|IICyNUwhVUSPMjDhcoQhfGinIIDyc{1ieG:ydH;0bYMhSkG[IHHu[EBRXU2DIIDyc5RmcW6|wrC= NUWyXnVWOjR{NECyNFM>
UoCB6 NWXVZWt4TnWwY4Tpc44hSXO|YYm= M{jZVlUwOTBizszN MnPXcIVi\HNidH:gZUB{fWK|dHHueIlidCCjY3P1cZVt[XSrb36gc4YhfGinIIC1N{Bxem:2ZXnuJIF{KHenbHygZZMhfGinIHX4dJJme3Orb36gc4YhcXS|IHTpdoVkfCC2YYLn[ZR{KHB{MTygUWROOiCjbnSgeIhmKHC{bz3hdI9xfG:2aXOgRmFZKGGwZDDQWW1CKHC{b4TlbY5{yqB? Ml\ONlQzPDB{MEO=
AT2 MYjD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MoPiNE0zPSEQvF2= MX7pcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6 M4[z[|I1OjRyMkCz
REH NGjIZWRE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MX2wMVI2KM7:TR?= MmLZbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>? M3PPW|I1OjRyMkCz
UoCB6 MlXYR4VtdCCYaXHibYxqfHliQYPzZZk> M3[1c|AuOjVizszN NHLvN29qdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 NYXlTldyOjR{NECyNFM>
A2780 M1e4XWZ2dmO2aX;uJGF{e2G7 MlPjOU8yOC9{MDFOwG0> M4H0SFI1KGh? MoPMeZBz\We3bHH0[ZMheDV|LDDNSG0zNCCyMkGgZY5lKESUNTDwdo91\WmwIHzleoVteyCmb4PlJIRmeGWwZHXueIx6yqB? MXqyOFE{PjF2Nx?=
H460 NUXJUZhPTnWwY4Tpc44hSXO|YYm= MXK1M|ExNzJyIN88US=> NXTLbHVyOjRiaB?= NVrzUVNZfXC{ZXf1cIF1\XNicEWzMEBOTE1{LDDwNlEh[W6mIFTSOUBxem:2ZXnuJIxmfmWuczDkc5NmKGSncHXu[IVvfGy7wrC= MoraNlQyOzZzNEe=
Lovo  MUfGeY5kfGmxbjDBd5NigQ>? M4\0d|UwOTBxMkCg{txO MmHmNlQhcA>? NXf2Z3FCfXC{ZXf1cIF1\XNicEWzMEBOTE1{LDDwNlEh[W6mIFTSOUBxem:2ZXnuJIxmfmWuczDkc5NmKGSncHXu[IVvfGy7wrC= NXHTeVZoOjRzM{[xOFc>
A2780 M1vWPWFxd3C2b4Ppd{BCe3OjeR?= NH7BdJY2NzFyL{KwJO69VQ>? MnrqNlQhcA>? Mnnj[Y5p[W6lZYOgZZBweHSxc3nzJIlv\HWldHnvckBjgSCGMk[5TE9GOTl3UjDveoVzKHKqVGLBTWw> NET3TYIzPDF|NkG0Oy=>
H460 NIDySJNCeG:ydH;zbZMhSXO|YYm= MmXkOU8yOC9{MDFOwG0> NYLZTGNjOjRiaB?= MVrlcohidmOnczDhdI9xfG:|aYOgbY5lfWO2aX;uJIJ6KER{NknIM2UyQTWUIH;2[ZIhemiWUlHJUC=> MYCyOFE{PjF2Nx?=
Lovo  M{TYZWFxd3C2b4Ppd{BCe3OjeR?= M1KwPVUwOTBxMkCg{txO MVuyOEBp NYLXWGxb\W6qYX7j[ZMh[XCxcITvd4l{KGmwZIXjeIlwdiCkeTDENlY6UC:HMUm1VkBwfmW{IILoWHJCUUx? M{KxcFI1OTN4MUS3

... Click to View More Cell Line Experimental Data

In vivo Oral administration of Nutlin-3 at 200 mg/kg twice daily for 3 weeks significantly inhibits the tumor growth of SJAS-1 xenografts by 90%, comparable with the effect of doxorubicin treatment with 81% inhibition of tumor growth. [1]

Protocol

Kinase Assay:

[1]

+ Expand

Biacore study:

Competition assay is performed on a Biacore S51. A Series S Sensor chip CM5 is utilized for the immobilization of a PentaHis antibody for capture of the His-tagged p53. The level of capture is ~200 response units (1 response unit corresponds to 1 pg of protein per mm2). The concentration of MDM2 protein is kept constant at 300 nM. Nutlin-3 is dissolved in DMSO at 10 mM and further diluted to make a concentration series of Nutlin-3 in each MDM2 test sample. The assay is run at 25 °C in running buffer (10 mM Hepes, 0.15 M NaCl, 2% DMSO). MDM2-p53 binding in the presence of Nutlin-3 is calculated as a percentage of binding in the absence of Nutlin-3 and IC50 is calculate
Cell Research:

[1]

+ Expand
  • Cell lines: HCT116, RKO, SJSA-1, SW480, and MDA-MB-435
  • Concentrations: Dissolved in DMSO, final concentrations ~ 30 μM
  • Incubation Time: 8, 24, and 48 hours
  • Method:

    Cells are exposed to various concentrations of Nutlin-3 for 8, 24 and 48 hours. The transcriptional levels of p21 and MDM2 genes are analyzed by real-time PCR, and protein levels by western blotting. Cell viability is measured by the MTT assay. Cell apoptosis is determined by terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end labeling (TUNEL) staining with flow cytometry and fluorescence microscopy.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: Athymic female nude mice (Nu/Nu-nuBR) injected subcutaneously with SJSA-1 cells
  • Formulation: Formulated in 2% Klucel, 0.5% Tween 80
  • Dosages: 200 mg/kg
  • Administration: Orally, twice a day
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (171.96 mM)
Ethanol 30 mg/mL (51.59 mM)
Water Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 581.5
Formula

C30H30Cl2N4O4

CAS No. 890090-75-2
Storage powder
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Is this a racemic mixture of Nutlin-3a and Nutlin-3b or just the Nutlin-3a enantiomer?

  • Answer:

    It is a racemate.

Mdm2 Signaling Pathway Map

Related Mdm2 Products

Tags: buy Nutlin-3 | Nutlin-3 supplier | purchase Nutlin-3 | Nutlin-3 cost | Nutlin-3 manufacturer | order Nutlin-3 | Nutlin-3 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID